PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Docket No: O96716

Yoshinobu YAMAZAKI

Group Art Unit: 1614

Appln. No.: 10/598,533

Examiner: BLAKELY III, NELSON

CLARENCE

Confirmation No.: 6983 Filed: September 1, 2006

For:

MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF OVERACTIVE BLADDER ACCOMPANYING NERVOUS DISORDER

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore

Atty. Docket No. Q96716

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

Appln No.: 10/598,533

Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The attached references were cited in a corresponding Japanese Office Action dated December 6, 2011.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC 2100 Pennsylvania Avenue, N.W. Washington, DC 20037 Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373

Date: January 31, 2012

/Jennifer M. Hayes Jennifer M. Hayes Registration No. 40,641

INFORMATION DISCLOSURE CERTIFICATION STATEMENT

Application Number	10/598,533	
Filing Date	September 1, 2006	
First Named Inventor	Yoshinobu YAMAZAKI	
Group Art Unit	1614	
Examiner Name	BLAKELY III, NELSON CLARENCE	
Attorney Docket Number	Q96716	

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CPR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

That each item of information contained in the Information Disclosure Statement filed concurrently herewith: (i) was first cited in any communication from a patent office in a counterpart foreign or international application or from the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement; or (ii) is a communication that was issued by a patent office in a counterpart foreign or international application or by the Office, and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. See 37 CFR 1.704(d).

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

☐ None

SUGHRUE MION, PLLC 2100 Pennsylvania Avenue, N.W. Washington, DC 20037 Telephone: (202) 293-7860 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jennifer M. Hayes/	Date	January 31, 2012
Name/Print	Jennifer M. Hayes	Registration Number	40,641